An observational study in Type1diabetes, sponsored by Stanford University. Withdrawn at 1 site in United States. Open to participants aged 6 Months to 21 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Stanford University · Observational
The study was determined to be non-human subject research and quality improvement program.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Diabetes Mellitus, Type 1 by Stanford University — 4 open to participants now, 6 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Stanford University.
Among the 31 studies in Diabetes Mellitus, Type 1 by Stanford University, this one is one of 2 that started in 2024, is one of 3 observational ones, and was the 25th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →4 of the 31 studies in Diabetes Mellitus, Type 1 by Stanford University are open now, in 1 country. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 18–60 · Healthy volunteers
Stanford University · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 12+ · Women only
Stanford University · Sites in United States
Ages 2–26
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 6 Months to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 24 across the 28 interventional studies, 30 across the 3 observational. Of the 21 that completed or were terminated, 12 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
3 of the studies in Diabetes Mellitus, Type 1 by Stanford University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07501338Stanford UniversityEarly Automated Insulin Delivery (AID) Pilot for Newly Diagnosed T1D | 2027-03 |
| NCT06329375Stanford UniversityFood Insecurity Reduction & Strategy Team | 2027-04-15 |
| NCT07226583Stanford UniversityUsing a Personalized Decision Support Tool to Help People With Type 1 Diabetes Manage Exercise | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 31 studies in Diabetes Mellitus, Type 1 by Stanford University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of the 4T program is to implement proven methods and emerging diabetes technology into clinical practice to sustain tight glucose control from the onset of type 1 diabetes (T1D) and optimize patient-reported and psychosocial outcomes. The investigators will expand the 4T (Teamwork, Targets, Technology, and Tight Control) program to all patients seen at Stanford Pediatric Diabetes Endocrinology as the standard of care. Disseminating the 4T program as the standard of care will optimize the benefits of diabetes technology by lowering HbA1c, improving PROs, and reducing disparities.
The investigators propose a multi-disciplinary diabetes team approach to utilize existing and emerging diabetes technologies and education strategies to implement scalable diabetes care with the goal of maintaining tight control for newly diagnosed Pediatric T1D patients. Successful T1D care is more than glucose control; the 4T program will closely monitor psychosocial and patient-reported outcomes (PROs) through the established psychosocial screening and treatment program. The 4T program will utilize automated approaches to analyze glucose profiles developed in conjunction with the Stanford SURF (Systems Utilization Research For Stanford Medicine) team. The 4T program will tailor intervention to those patients most in need of team support employing a broad range of behavioral and technology supports, strengths of the Stanford Pediatric Diabetes program. The 4T program approach more precisely adapts care to patient needs and optimizes glucose and psychosocial outcomes.
Therefore, the investigators propose to expand the diabetes team approach (Teamwork, Targets, and Technology for Tight Control: 4T), which utilizes existing diabetes technologies and education strategies to implement and standardize goal-oriented diabetes care for newly diagnosed pediatric T1D patients, to a standard of care program at Stanford pediatric diabetes clinics. The Stanford diabetes team has revised the diabetes education approach to set clear and tighter targets at new-onset through the early phase of T1D and to be aggressive with the intensification of control as insulin needs and care demands increase. The 4T Sustainability program will further standardize T1D team care while allowing for personalization based on patient/family needs with the goal of optimizing glucose and psychosocial outcomes. (NOTE: the current protocol [IRB #52812] focuses on early initiation of CGM as the key technology for glucose monitoring. The 4T program is designed to be flexible to incorporate emerging technologies as they become available for patient care. For example, automated insulin delivery systems will be supported as part of the program). To make the 4T Sustainability Program a true standard of care program, remote patient monitoring (RPM) of the CGM data and CDCES-tailored patient contacts will be billed using RPM billing codes. These RPM billing codes have received hospital compliance approval, and billing workflows will be available in LPCH EPIC.
Personalized Goals and Automated Identification for Need for Insulin Changes in New Onsets: Data collected by continuous glucose monitoring (CGM) can improve the quality of patient care; facilitate the use of telemedicine to reduce costs and improve convenience; and improve the understanding of how daily behaviors shape long-term outcomes.
Modern Electronic Health Records (EHRs) can potentially be used to reduce the workload necessary to care for patients; reduce error rates by automating alerts; and facilitate continuous evaluation and improvement of provider adherence to best-practices. To be practical and scalable, these systems must provide actionable information and require relatively few inputs. The investigators have developed stand-alone tools that analyze CGM time series data to set personalized care goals and to determine when glucose values increase, or insulin dose adjustments and other care adaptations are required. To allow Stanford and the broader community to realize the full potential of such tools, the investigators will implement and refine their use in our clinics:
All patients seen at Stanford Children's Diabetes Clinic diagnosed with Type 1 Diabetes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion criteria includes all youth with new onset T1D seen in the Stanford/Lucile Packard Children's Hospital ages 6 months-21 years of age. The program will also be offered to pediatric patients with existing T1D who wear a CGM or want to start a CGM and receive RPM. We intend to include all possible patients with the goal of maximizing generalizability of the results and 4T program. (NOTE: We will include children and families who speak all languages using the Stanford interpreter services so as to have the greatest generalizability of the research. Questionnaires will only be given to English and Spanish speakers.)
Patient or guardian must own and operate a compatible smart device/phone to send data from the CGM into the HIPAA-compliant RPM-care model for data analysis and review by a care team member.
Exclusion Criteria:
1\. Implement the 4T program as standard of care at Stanford Diabetes clinics, including Continuous Glucose Monitoring (CGM) and Remote Patient Monitoring (RPM) within the first 30 days after T1D diagnosis to reduce the rise in HbA1c trajectory observed 4-12 months post-diagnosis.
Other: CGM and RPM
1\. Implement the 4T program as standard of care at Stanford Diabetes clinics, including Continuous Glucose Monitoring (CGM) and Remote Patient Monitoring (RPM) within the first 30 days after T1D diagnosis to reduce the rise in HbA1c trajectory observed 4-12 months post-diagnosis.
HbA1c trajectory observed 4-12 months post-diagnosis
Implement 4T program as standard of care, including Continuous Glucose Monitoring (CGM) and Remote Patient Monitoring (RPM) within the first 30 days after T1D diagnosis to reduce the rise in HbA1c trajectory observed 4-12 months post-diagnosis.To address Aim 1, the investigators will use generalized linear mixed effects regression techniques that allows for two piecewise linear slopes of HbA1c levels to be estimated from diagnosis to 4 months and from 4 to 12 months post-diagnosis to determine the effect of the 4T diabetes intervention on changes in HbA1c between 4- and 12-months post-diagnosis and compare observed increases to those in our internal and external contemporaneous controls via separate models. Each mixed effects model will include a subject-specific random effect to account for the correlation of HbA1c within a person over time, and these models will be adjusted for sex, age, ethnicity, and insurance type at diagnosis.
Time frame: 4-12 months post TID diagnosis
Diabetes distress measured at baseline and 12 months post-diagnosis.
The investigators will utilize generalized linear mixed effects models to address Aim 2. More specifically, the investigators will regress diabetes distress index on use of CGM. Such a model will include a subject-specific random effect and an indicator of whether the patient utilized CGM technologies. Assuming the ratio of using CGM technology is 0.6 and SD of diabetes distress score is 3, we have 90% power to detect a two-unit reduction on mean diabetes distress score.
Time frame: baseline and 12 months post Type 1 Diabetes diagnosis
Plan to share: No
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for Jan 2027, 32 months after the start.
How these figures are worked out, and which studies are left out of them.
The study was determined to be non-human subject research and quality improvement program.
The study was determined to be non-human subject research and quality improvement program.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.